These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23460751)

  • 41. CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy.
    Carvalho-Silva WHV; Andrade-Santos JL; Guedes MCDS; Crovella S; Guimarães RL
    Gene; 2020 May; 741():144568. PubMed ID: 32165289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence.
    Avettand-Fenoel V; Lechenadec J; Diallo MS; Fillion M; Melard A; Samri A; Dollfus C; Blanche S; Faye A; Amokrane K; Autran B; Buseyne F; Warszawski J; Frange P;
    Clin Infect Dis; 2021 Dec; 73(11):e4214-e4222. PubMed ID: 34355738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure.
    Ding J; Liu Y; Lai Y
    Front Immunol; 2021; 12():688747. PubMed ID: 34122453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased susceptibility of peripheral blood mononuclear cells from individuals heterozygous for a mutant CCR5 allele to HIV infection.
    Kim A; Pettoello-Mantovani M; Goldstein H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):145-9. PubMed ID: 9768623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
    Agrawal L; Vanhorn-Ali Z; Alkhatib G
    J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo.
    Sebastian NT; Zaikos TD; Terry V; Taschuk F; McNamara LA; Onafuwa-Nuga A; Yucha R; Signer RAJ; Riddell J; Bixby D; Markowitz N; Morrison SJ; Collins KL
    PLoS Pathog; 2017 Jul; 13(7):e1006509. PubMed ID: 28732051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myeloid and CD4 T Cells Comprise the Latent Reservoir in Antiretroviral Therapy-Suppressed SIVmac251-Infected Macaques.
    Abreu CM; Veenhuis RT; Avalos CR; Graham S; Parrilla DR; Ferreira EA; Queen SE; Shirk EN; Bullock BT; Li M; Metcalf Pate KA; Beck SE; Mangus LM; Mankowski JL; Mac Gabhann F; O'Connor SL; Gama L; Clements JE
    mBio; 2019 Aug; 10(4):. PubMed ID: 31431552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
    Allers K; Schneider T
    Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Haemopoietic cell transplantation in patients living with HIV.
    Ambinder RF; Capoferri AA; Durand CM
    Lancet HIV; 2020 Sep; 7(9):e652-e660. PubMed ID: 32791046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
    HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
    Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
    PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
    Equils O; Garratty E; Wei LS; Plaeger S; Tapia M; Deville J; Krogstad P; Sim MS; Nielsen K; Bryson YJ
    J Infect Dis; 2000 Sep; 182(3):751-7. PubMed ID: 10950768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders.
    Kwon M; Bailén R; Balsalobre P; Jurado M; Bermudez A; Badiola J; Esquirol A; Miralles P; López-Fernández E; Sanz J; Yañez L; Colorado M; Piñana JL; Dorado N; Solán L; Martínez Laperche C; Buño I; Anguita J; Serrano D; Díez-Martin JL;
    AIDS; 2019 Jul; 33(9):1441-1447. PubMed ID: 30932952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.
    Jin Q; Marsh J; Cornetta K; Alkhatib G
    J Gen Virol; 2008 Oct; 89(Pt 10):2611-2621. PubMed ID: 18796731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and the role of CCR5Δ32 heterozygosity in disease progression in HIV positive patients in the Czech Republic.
    Sácká L; Hodek J; Machala L; Malý M; Weber J
    Epidemiol Mikrobiol Imunol; 2019; 68(3):138-143. PubMed ID: 31914779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CCR5Delta32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivo.
    Agrawal L; Jin Q; Altenburg J; Meyer L; Tubiana R; Theodorou I; Alkhatib G
    J Virol; 2007 Aug; 81(15):8041-9. PubMed ID: 17522201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease.
    Hu J; Feng Y; Ma P; Lai Y
    Curr Stem Cell Res Ther; 2019; 14(7):591-597. PubMed ID: 31120000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy.
    Araínga M; Edagwa B; Mosley RL; Poluektova LY; Gorantla S; Gendelman HE
    Retrovirology; 2017 Mar; 14(1):17. PubMed ID: 28279181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.
    Cummins NW; Rizza S; Litzow MR; Hua S; Lee GQ; Einkauf K; Chun TW; Rhame F; Baker JV; Busch MP; Chomont N; Dean PG; Fromentin R; Haase AT; Hampton D; Keating SM; Lada SM; Lee TH; Natesampillai S; Richman DD; Schacker TW; Wietgrefe S; Yu XG; Yao JD; Zeuli J; Lichterfeld M; Badley AD
    PLoS Med; 2017 Nov; 14(11):e1002461. PubMed ID: 29182633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells.
    Hütter G; Ganepola S
    ScientificWorldJournal; 2011 May; 11():1068-76. PubMed ID: 21552772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.